Canakinumab
- BNF:
- 8.2.4
- Status:
- Do Not Prescribe (DNP)
- Decision Date:
- None
Comments
Do Not Prescribe (DNP):
- NICE TA281: for treating gouty arthritis attacks and reducing the frequency of subsequent attacks. (Terminated appraisal). (Decision date - May 2013).
- NICE TA302: for treating systemic juvenile idiopathic arthritis. (Decision date - December 2013).
- NHSE Clinical Commissioning Policy SSC2437: Canakinumab for patients
with Still’s disease refractory to anakinra and tocilizumab (adults and
children 2 years and over)- The policy confirms that canakinumab is not
routinely commissioned for these patients. (Decision date - November 2022).
Black Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
search again